Stephen Hoge - 23 Feb 2022 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
President
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
23 Feb 2022
Net transactions value
-$2,681,134
Form type
4
Filing time
25 Feb 2022, 15:39:28 UTC
Previous filing
15 Feb 2022
Next filing
03 Mar 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $54,500 +5,000 +0.31% $10.90* 1,615,791 23 Feb 2022 Direct F1
transaction MRNA Common Stock Options Exercise $9,900 +10,000 +0.62% $0.9900* 1,625,791 23 Feb 2022 Direct F1
transaction MRNA Common Stock Sale $244,513 -1,802 -0.11% $135.69 1,623,989 23 Feb 2022 Direct F1, F2
transaction MRNA Common Stock Sale $505,886 -3,698 -0.23% $136.80 1,620,291 23 Feb 2022 Direct F1, F3
transaction MRNA Common Stock Sale $317,009 -2,300 -0.14% $137.83 1,617,991 23 Feb 2022 Direct F1, F4
transaction MRNA Common Stock Sale $111,184 -800 -0.05% $138.98 1,617,191 23 Feb 2022 Direct F1, F5
transaction MRNA Common Stock Sale $13,967 -100 -0.01% $139.67 1,617,091 23 Feb 2022 Direct F1
transaction MRNA Common Stock Sale $28,238 -200 -0.01% $141.19 1,616,891 23 Feb 2022 Direct F1, F6
transaction MRNA Common Stock Sale $113,856 -800 -0.05% $142.32 1,616,091 23 Feb 2022 Direct F1, F7
transaction MRNA Common Stock Sale $766,380 -5,300 -0.33% $144.60 1,610,791 23 Feb 2022 Direct F1, F8
transaction MRNA Common Stock Options Exercise $54,500 +5,000 +0.31% $10.90* 1,615,791 24 Feb 2022 Direct F1
transaction MRNA Common Stock Sale $699,000 -5,000 -0.31% $139.80 1,610,791 24 Feb 2022 Direct F1
holding MRNA Common Stock 4,116 23 Feb 2022 By Valhalla, LLC
holding MRNA Common Stock 151,933 23 Feb 2022 By Trust F9

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5,000 -3.7% $0.000000 131,972 23 Feb 2022 Common Stock 5,000 $10.90 Direct F1, F10
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -10,000 -7.8% $0.000000 117,431 23 Feb 2022 Common Stock 10,000 $0.9900 Direct F1, F10
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5,000 -3.8% $0.000000 126,972 24 Feb 2022 Common Stock 5,000 $10.90 Direct F1, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $135.28 to $136.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $136.32 to $137.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $137.53 to $138.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $138.65 to $139.44. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F6 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $140.70 to $141.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $141.90 to $142.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F8 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $144.34 to $145.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F9 These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
F10 This option is fully vested and exercisable.